HomeCompareALIM vs KMB

ALIM vs KMB: Dividend Comparison 2026

ALIM yields 36.10% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALIM wins by $141.2K in total portfolio value
10 years
ALIM
ALIM
● Live price
36.10%
Share price
$5.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$187.1K
Annual income
$29,005.40
Full ALIM calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — ALIM vs KMB

📍 ALIM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALIMKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALIM + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALIM pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALIM
Annual income on $10K today (after 15% tax)
$3,068.59/yr
After 10yr DRIP, annual income (after tax)
$24,654.59/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, ALIM beats the other by $20,224.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALIM + KMB for your $10,000?

ALIM: 50%KMB: 50%
100% KMB50/50100% ALIM
Portfolio after 10yr
$116.5K
Annual income
$17,108.36/yr
Blended yield
14.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ALIM
No analyst data
Altman Z
-1.4
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALIM buys
0
KMB buys
0
No recent congressional trades found for ALIM or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALIMKMB
Forward yield36.10%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$187.1K$45.9K
Annual income after 10y$29,005.40$5,211.33
Total dividends collected$136.3K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ALIM vs KMB ($10,000, DRIP)

YearALIM PortfolioALIM Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$14,310$3,610.11$11,314$613.68+$3.0KALIM
2$20,140$4,828.13$12,865$759.19+$7.3KALIM
3$27,900$6,350.55$14,709$943.96+$13.2KALIM
4$38,075$8,222.00$16,919$1,180.17+$21.2KALIM
5$51,227$10,486.45$19,588$1,484.33+$31.6KALIM
6$67,999$13,185.62$22,838$1,879.06+$45.2KALIM
7$89,116$16,357.51$26,832$2,395.60+$62.3KALIM
8$115,389$20,035.00$31,788$3,077.63+$83.6KALIM
9$147,711$24,244.58$38,000$3,986.82+$109.7KALIM
10$187,056$29,005.40$45,872$5,211.33+$141.2KALIM

ALIM vs KMB: Complete Analysis 2026

ALIMStock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Full ALIM Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ALIM vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALIM vs SCHDALIM vs JEPIALIM vs OALIM vs KOALIM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.